1. Clinical & Scientific Overview
Ibuprofen (TIP-MED-000106, Reference Code [7.4]) is classified under
Pain, Inflammation, Rheumatology & Gout Medicines (Ch 07) as a Non-Steroidal Anti-Inflammatory Drug (NSAID); Propionic Acid Derivative (Non-Selective COX-1 & COX-2 Inhibitor).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 07 [7.4], p. 80): Brufen (Abbott), Ibugesic (Cipla); In FDC with Paracetamol: Combiflam (Sanofi—Ibuprofen 400 mg + Paracetamol 325 mg), Ibugesic Plus, Flexon — Strengths & Dosage Forms: Oral Film-Coated Tablets: 200 mg, 400 mg, 600 mg; Oral Suspension: 100 mg/5 mL
Oral Film-Coated Tablets: 200 mg, 400 mg, 600 mg; Oral Suspension: 100 mg/5 mL
3. Mechanism of Action & Pharmacodynamics
Non-Steroidal Anti-Inflammatory Drug (NSAID); Propionic Acid Derivative (Non-Selective COX-1 & COX-2 Inhibitor) acting on target receptor/enzyme pathways in Pain, Inflammation, Rheumatology & Gout Medicines (Ch 07): clinical efficacy is mediated via Non-Steroidal Anti-Inflammatory Drug (NSAID); Propionic Acid Derivative (Non-Selective COX-1 & COX-2 Inhibitor) for Acute mild-to-moderate inflammatory pain (dental pain, dysmenorrhoea, headache/migraine, soft-tissue trauma, postoperative pain, arthritic flares) and fever (when paracetamol alone is insufficient and dengue is excluded)..
4. Therapeutic Indications & Evidence-Supported Uses
- Acute mild-to-moderate inflammatory pain (dental pain, dysmenorrhoea, headache/migraine, soft-tissue trauma, postoperative pain, arthritic flares) and fever (when paracetamol alone is insufficient and dengue is excluded)
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: Analgesic/Antipyretic: 200 mg to 400 mg every 6 to 8 hours as needed (max OTC dose 1200 mg/day). Anti-inflammatory (Arthritis): 400 mg to 600 mg three times daily (Maximum 2400 mg/day). Follow physician prescription.
Administration & Meal Timing: Strictly WITH or immediately AFTER food or milk to reduce gastric mucosal erosion. | Every 6–8 hours after meals as needed.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Avoid if eGFR <30–45 mL/min or in dehydrated patients. Hepatic: Avoid in severe hepatic impairment/cirrhosis (high risk of variceal bleed and hepatorenal syndrome).
Renal: Avoid if eGFR <30–45 mL/min or in dehydrated patients. Hepatic: Avoid in severe hepatic impairment/cirrhosis (high risk of variceal bleed and hepatorenal syndrome).
Renal: Avoid if eGFR <30–45 mL/min or in dehydrated patients. Hepatic: Avoid in severe hepatic impairment/cirrhosis (high risk of variceal bleed and hepatorenal syndrome).
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated in active peptic ulcer/GI bleed, severe heart failure, post-CABG surgery, severe renal/hepatic failure, aspirin-sensitive asthma, third trimester of pregnancy (causes premature closure of foetal ductus arteriosus), and suspected Dengue/viral haemorrhagic fever.
Key Clinical Precautions: Renal: Avoid if eGFR <30–45 mL/min or in dehydrated patients. Hepatic: Avoid in severe hepatic impairment/cirrhosis (high risk of variceal bleed and hepatorenal syndrome).
8. Adverse Effects Profile
- Epigastric burning, nausea, heartburn, dizziness, fluid retention, mild BP increase.
- Peptic ulcer haemorrhage/perforation, acute renal failure (renal papillary necrosis/interstitial nephritis), cardiovascular thrombotic events (especially at high doses ≥2400 mg/day), bronchospasm.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- CRITICAL CARDIOPROTECTION INTERACTION WITH ASPIRIN 75/150 mg: Ibuprofen reversibly occupies the platelet COX-1 docking site and physically blocks low-dose Aspirin from irreversibly acetylating platelets, abolishing aspirin's heart-attack protection! Avoid ibuprofen in patients on Ecosprin (or give immediate-release aspirin ≥30 min before or ≥8 hours after ibuprofen, though enteric-coated Ecosprin still interacts even when spaced!)
- Standard NSAID interactions with ACEI/ARBs, diuretics, anticoagulants, lithium, and methotrexate
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Warn every CGHS cardiac patient taking Ecosprin 75/150 mg: 'Never pop a Combiflam or Brufen tablet for headache or toothache—ibuprofen blocks Ecosprin from protecting your heart and doubles the risk of stomach bleeding. Use plain Paracetamol (Dolo/Calpol) instead!'
- Meal & Clock Timing Instruction: Strictly WITH or immediately AFTER food or milk to reduce gastric mucosal erosion. (Every 6–8 hours after meals as needed.)
- Missed Dose Protocol: Taken SOS; do not double.
- Geriatric Dispensing Pearl: Avoid in elderly patients due to GI bleeding, renal impairment, and direct antagonism of cardioprotective aspirin.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Film-Coated Tablets: 200 mg, 400 mg, 600 mg; Oral Suspension: 100 mg/5 mL
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 07 [7.4] (p. 80)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.